Table 2.
Multivariable Cox regression of loco–regional tumour control for the 2-metagene signature, treatment, their interaction term, and relevant clinical parameters for the pooled matched dataset (n = 216). Significant p-values are marked in bold.
| Parameter | Coefficient (ß) | Loco–Regional Control HR (95 % CI) |
p-Value |
|---|---|---|---|
| 2-Gene signature | |||
| Gene classifier (high vs. low risk [b]) | 1.22 | 3.42 (1.47–7.97) | 0.004 |
| Treatment status (PORT-C vs. PORT [b]) | −0.30 | 0.74 (0.35–1.58) | 0.44 |
| Gene classifier × Treatment status | −1.73 | 0.18 (0.04–0.82) | 0.027 |
| 2-Gene signature and clinical parameters | |||
| Gene classifier (high vs. low risk [b]) | 1.19 | 3.29 (1.37–7.91) | 0.007 |
| Treatment status (PORT-C vs. PORT [b]) | −0.57 | 0.56 (0.24–1.33) | 0.19 |
| Gene classifier × Treatment status | −1.81 | 0.16 (0.03–0.78) | 0.023 |
| T stage (3, 4 vs. 1, 2 [b]) | 0.99 | 2.68 (1.33–5.40) | 0.005 |
| Tumour localization (oral cavity vs. others [b]) | 0.58 | 1.79 (0.88–3.64) | 0.11 |
| N stage (2, 3 vs. 0, 1 [b]) | 0.38 | 1.46 (0.65–3.27) | 0.36 |
| R status (1 vs. 0 [b]) | 0.40 | 1.49 (0.69–3.30) | 0.33 |
| ECE status (1 vs. 0 [b]) | 0.48 | 1.61 (0.66–3.92) | 0.29 |
| p16 overexpression (1 vs. 0 [b]) | −0.97 | 0.38 (0.15–0.94) | 0.037 |
[b] Baseline class.